Skip to main content
Sign In

University of Colorado Denver


Christina Aquilante, PharmD, FCCP

Associate Professor, Department of Pharmaceutical Sciences

Dr. Christina Aquilante

Mailing address:

University of Colorado 
Skaggs School of Pharmacy and Pharmaceutical Science
Mail Stop C238 
12850 E. Montview Blvd. V20-4103 
Aurora, CO 80045

Office Location:

Pharmacy and Pharmaceutical Sciences Building (V20) 
Fourth Floor 
Room 4103

Lab Location:

Pharmacy and Pharmaceutical Sciences Building (V20) 
Fourth Floor 
Room 4420A


Training and Education:

  • PharmD, University of North Carolina at Chapel Hill
  • Pharmacy Practice Residency, Shands Hospital at the University of Florida
  • Post-PharmD Research Fellowship in Cardiovascular Pharmacogenomics, University of Florida College of Pharmacy
  • Certificate in Clinical Science, University of Colorado Clinical Science Graduate Program

Research Interest:

Dr. Aquilante's patient-oriented clinical research program is aimed at identifying pharmacogenetic determinants of drug disposition, response, and adverse effects in cardiovascular and metabolic diseases. Her research has been funded by the National Institutes of Health, American Heart Association, American College of Clinical Pharmacy, American Association of Colleges of Pharmacy, pharmaceutical industry, and private foundations. 

Currently, Dr. Aquilante’s clinical studies are focused on heart transplant recipients and patients with advanced heart failure. The primary goal of her work is to identify genetic predictors of drug disposition (pharmacokinetics), response (pharmacodynamics) and adverse effects in heart transplant recipients. She is also interested in identifying factors that influence medication regimen complexity and adherence in the heart transplant population. Recently, Dr. Aquilante has expanded her research program to include a cross-disciplinary and translational component. This approach is being used to elucidate mechanisms underlying left ventricular assist device (LVAD)-related adverse effects in patients with advanced heart failure.


Professional ProgramS:

  • PHRD 5915 Modern Drug Design and Action, Lecturer
  • PHRD 6095 Pharmacotherapy 3, Lecturer
  • PHRD 6915/7015 Seminar Research Course, Preceptor
  • PHRD 7025 Pharmacogenomics (Entry-Level PharmD Program), Course Coordinator and Lecturer
  • PHRD 7995 Clinical Capstone, Lecturer
  • P4 APPE Rotation—Clinical Research and Pharmacogenomics
  • PRDO 7780 Pharmacogenomics (North American-Trained and International-Trained PharmD Programs), Course Coordinator and Lecturer

Graduate Programs:

  • PHSC/TXCL 7310 Fundamentals of Pharmaceutical Sciences, Lecturer
  • PHSC/TXCL 7400 Ethical Issues in Toxicology and Pharmaceutical Sciences, Lecturer
  • PHSC/TXCL 7665 Pharmacokinetic Principles and Applications, Lecturer
  • CLSC 6260 Conducting Clinical Trials for Investigators, Lecturer
  • CLSC 7500 Practical Application of Molecular Biology Techniques for the Clinical Investigator, Lecturer
  • EPID 6642, Genetics in Public Health, Lecturer

Professional Awards and Service:

  • New Investigator Award, American College of Clinical Pharmacy (2008)
  • Chair, University of Colorado School of Pharmacy Admissions Committee (2010-2014)
  • Fellow, American College of Clinical Pharmacy (2015)
  • Vice Chair, Task Force on Collaborative Research Opportunities, American College of Clinical Pharmacy (2015-2016)
  • Chair-Elect, Pharmacogenomics Special Interest Group (SIG), American Association of Colleges of Pharmacy (2016-2017)
  • Co-Chair, Colorado Pharmacogenomics Implementation Committee
  • Member, Inter-Society Coordinating Committee for Practitioner Education in Genetics and Genomics (ISCC), National Human Genome Research Institute (NHGRI/NIH)

Representative Publications:

  • Aquilante CL, Kosmiski LA, Bourne DWA, et al.  Impact of the CYP2C8*3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.  Br J Clin Pharmacol. 2013; 75(1):217-26. 
  • Aquilante CL, Niemi M, Gong L, Altman RB, Klein TE.  PharmGKB summary:  very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.  Pharmacogenet Genomics. 2013; 23(12):721-8.
  • Aquilante CL, Page RL, Vu A, Roscoe N, Wolfel EE, Lindenfeld JA. Comparison of Office, Home, and Ambulatory Blood Pressure in Heart Transplant Recipients.  J Card Fail. 2014; 20(8):602-10. 
  • Vu A, Kosmiski LA, Beitelshees AL, Prigeon R, Sidhom MS, Bredbeck B, Predhomme J, Deininger K, Aquilante CL.  Pharmacodynamic effects of low-dose pioglitazone in nondiabetic patients with the metabolic syndrome.  Pharmacotherapy. 2016; 36(3):252-62.
  • Deininger KM, Vu A, Page II, Ambardekar AV, Lindenfeld J, Aquilante CL. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients. Clin Transplant. 2016 Jun 17 [Epub ahead of print]  PMID: 27314545.
  • Bryant BM, Libby AM, Metz KR, Page RL II, Ambardekar AV, Lindenfeld J, Aquilante CL.  Evaluating patient-level medication regimen complexity over time in heart transplant recipients.  Ann Pharmacother.  2016 Jul 2 [Epub ahead of print]  PMID: 27371949.